Chong Kun Dang files patent trials: what it means for Chong Kun Dang stock

Published on 10/14/2026 at 06:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Chong Kun Dang filed four patent trials on October 10, 2026. For Chong Kun Dang stock, second-quarter revenue reached KRW 478.47 billion.

Patent defense and earnings calendar

Chong Kun Dang filed patent-scope trials against four generic competitors on October 10, 2026.
Second-quarter revenue reached KRW 478.47 billion and operating profit was KRW 18.62 billion.
Chong Kun Dang is scheduled to publish its next earnings report on November 12, 2026.

Chong Kun Dang, KR7185750007, Illustration mit AI erstellt.

Chong Kun Dang (KR7185750007) filed positive patent-scope trials against four generic competitors on October 10, 2026, according to Dailypharm. The action targets approved generic versions of Telminuvo, a fixed-dose hypertension treatment, and gives Chong Kun Dang stock a concrete product-protection issue to assess.

Patent defense targets four competitors

Chong Kun Dang asked the Intellectual Property Trial and Appeal Board to determine whether the generic products fall within the scope of its formulation patent. Dailypharm reported that Telminuvo generated annual prescription sales of KRW 50 billion to KRW 60 billion, making the patent dispute financially relevant to an established product.

The filing does not automatically block competing products from being sold, but it seeks a formal ruling on patent scope. That distinction matters because the legal step protects a potential enforcement position rather than immediately changing sales conditions.

Three dated corporate developments

On October 1, 2026, Chong Kun Dang presented Gitek, a stomach treatment launched after a phase 3 study, in a product symposium, as listed by ATS View. On October 8, the same company appeared in coverage of a share transfer involving three children of chairman Lee Jang-han, also recorded by ATS View. The October 10 patent action is the latest of the three developments.

What does the patent action protect?

The immediate financial reference is Telminuvo's KRW 50 billion to KRW 60 billion annual prescription-sales range, while the broader earnings picture is growing faster at the revenue level. The legal filing therefore adds a protection question to a business already balancing product expansion with margin pressure.

For the second quarter of 2026, Chong Kun Dang reported revenue of KRW 478.47 billion, up 10.00 percent year on year, and operating profit of KRW 18.62 billion, according to ATS View. Net income was KRW 19.99 billion in the same quarter, so the next results will show whether revenue growth translates into stronger operating profitability.

Next earnings date is November 12

Chong Kun Dang's next earnings report is scheduled for November 12, 2026, according to TradingView. MoneyToday reported on October 11, 2026 that third-quarter revenue was projected at KRW 485.70 billion, up 13.00 percent year on year, while operating-profit forecasts ranged from KRW 19.10 billion to KRW 23.00 billion because imported products and low-margin products affect the mix.

Market value on October 14

Chong Kun Dang Pharmaceutical traded on the Korea Exchange KOSPI market under ticker 185750, with a market capitalization of KRW 868.3 billion and a quoted price of KRW 65,900 on October 14, 2026. The valuation context leaves the October 10 patent filing and the November 12 earnings date as the two concrete dates for tracking the stock's next information.